Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
about
Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloofComputer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gammaHomocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementationWhich is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitusDual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsDiabetic cardiovascular disease: getting to the heart of the matter.RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.The association of higher levels of within-normal-limits liver enzymes and the prevalence of the metabolic syndrome.Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempolEffect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?Liver enzymes and metabolic syndrome: a large-scale case-control studyModulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory DiseasesDoes the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?Update on the use of fibrates: focus on bezafibrateP633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.Extraction efficiency, phytochemical profiles and antioxidative properties of different parts of Saptarangi (Salacia chinensis L.) - An important underutilized plant."The metabolic syndrome... is dead": these reports are an exaggeration.Effect of Withania somnifera on insulin sensitivity in non-insulin-dependent diabetes mellitus rats.Ficus carica leaf extract modulates the lipid profile of rats fed with a high-fat diet through an increase of HDL-C.
P2860
Q21246039-D80C6F88-869C-4477-B393-40F39E28A07CQ24599833-11D80F51-A14B-43A9-9514-CC603C65DB74Q24791545-19B63357-2645-4A70-9971-A85359079D38Q24804259-40778002-5D36-4123-856D-8D3D295A0D20Q24806075-39FF3D80-0797-4190-BFB4-1B8A406E47B9Q24816834-B5105768-F989-4669-AF2A-9A33E4F634B9Q28200554-8580BD06-4340-40A4-96D6-8113D7E000E6Q30451529-C50C9735-F0FC-49A4-A89F-734F0AD9841FQ34023922-51963A95-8FF3-4BAF-A9C1-32EE7B9CDDAFQ34043671-DD69340E-4225-4CF7-A307-14174F081DACQ34149341-60DBED1F-D349-4C5C-9412-706B87A01205Q34557349-ED0E2463-F684-40D3-9E30-C03F18D98030Q36411656-C1BFE990-E4A0-4D71-AF73-CEE2E27CB957Q36413611-46D8E6F6-2666-4FCE-9019-97DBC5FD0BC1Q36449677-1F88AD4C-311A-444F-93BD-31EEAB3AA05BQ36736985-7798C2AA-5DA8-4CE6-BFC1-ACB379F7B6D0Q36766923-E6DF0318-7DC0-45C9-9F87-6366710C93EDQ37290383-56D5C209-4142-459C-BC96-67BCCD7A7BC7Q37556648-5859F500-4881-44A8-856E-014334AD6976Q41682025-010176ED-E08F-421D-8EFA-13AFF3B4241CQ42593443-3C88AABE-9430-471E-BED4-8B6FC70D0D75Q46697472-3E0B206F-FF16-4775-B2CB-6AADA59DD503Q51054025-10050C12-78AE-4C91-A0B3-975B32752151
P2860
Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@ast
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@en
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@nl
type
label
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@ast
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@en
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@nl
prefLabel
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@ast
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@en
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@nl
P2093
P2860
P356
P1476
Metabolic syndrome and type 2 ...... tor activated receptors (PPAR)
@en
P2093
Alexander Tenenbaum
Enrique Z Fisman
Michael Motro
P2860
P2888
P356
10.1186/1475-2840-2-4
P407
P577
2003-03-23T00:00:00Z
P5875
P6179
1031381296